In 2004, after nearly two decades of preliminary studies, advocacy, and fundraising, MAPS received approval to begin their clinical trials for MDMA-AT for the treatment of PTSD. Nearly twenty years this first study, in November of 2022, MAPS PBC completed the collection of data for the final study required to file a New Drug Application. This panel presents the stories of the researchers and therapists who made history during this period, yielding the first completed Phase 3 study for a psychedelic drug in history. ACCESS LIMITATION: This session is open to qualified healthcare professionals only. DISCLAIMER: The safety and efficacy of MDMA-assisted therapy is currently under investigation. It has not yet been approved by the FDA or other regulatory authorities, does not work for everyone, and carries risks even in therapeutic settings.